Duchenne UK announces £46,930 to fund the expansion of clinical trial capacity at Birmingham Heartlands Hospital

Duchenne UK announces £46,930 in funding at Birmingham Heartlands Hospital. This funding will provide dedicated consultant time to DMD trials and provide physiotherapy equipment.

  • 18-May-2018

Duchenne UK will fund consultant time which will be dedicated to supporting clinical trials, as well as funding physiotherapy equipment for clinical trials.

We are delighted that Birmingham Heartlands Hospital is joining the DMD Hub and we are pleased to be able to fund this post and provide equipment. Duchenne UK have been in discussions with Birmingham Heartlands Hospital to support them to increase the number of DMD clinical trials they run, as part of our mission to expand clinical trial capacity in the UK through the DMD Hub. 

Yesterday Duchenne UK was pleased to be in Birmingham for the Rare Disease Symposium 2018. Our co-founder Alex Johnson spoke about the DMD Hub and how Duchenne UK is expanding clinical trial capacity. Dr Matthew Lumley from Pfizer discussed Project HERCULES, Duchenne UK’s collaborative project with seven pharmaceutical industry partners to get drugs to patients faster. The other members of Hercules are PTC Therapeutics International, Roche, Sarepta Therapeutics Inc, Solid Biosciences, Summit Therapeutics Plc and Wave Life Sciences USA, Inc.

The team met Dr Helen Roper, the principal investigator at Birmingham Heartlands Hospital, who said of our funding:

“We are very excited to have the funding of the DMD Hub, which will allow us to have some of our consultants’ time dedicated to clinical trials.”

We were also pleased to catch up with Anna Clark from Jack’s Mission and Emma Hallam from Alex’s Wish (pictured below), who we would like to thank for supporting the Birmingham Heartlands Hospital posts.

Alex Johnson, Emma Hallam, Dr Helen Roper and Anna Clark at the Birmingham Rare Disease Symposium 2018 yesterday.